International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic

Coles, C. E.; Aristei, C.; Bliss, J.; Boersma, L.; Brunt, A. M.; Chatterjee, S.; Hanna, G.; Jagsi, R.; Person, O. Kaidar; Kirby, A.; Mjaaland, I.; Meattini, I.; Luis, A. M.; Marta, G. N.; Offersen, B.; Poortmans, P.; Rivera, S.

doi:10.1016/j.clon.2020.03.006

All Outputs (3)

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer (2020)
Report
Brunt, A. M., Haviland, J. S., Sydenham, M., Agrawal, R. K., Algurafi, H., Alhasso, A., …Yarnold, J. R. (2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcom... Read More about Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., …Management Group, F. T. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395(10237), 1613 - 1626. https://doi.org/10.1016/S0140-6736%2820%2930932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri... Read More about Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic (2020)
Journal Article
Coles, C. E., Aristei, C., Bliss, J., Boersma, L., Brunt, A. M., Chatterjee, S., …Rivera, S. (2020). International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology, 32(5), 279-281. https://doi.org/10.1016/j.clon.2020.03.006

'No abstract'